Transfection Reagents & Equipment Market Worth $1.4 Billion By 2025

Transfection Reagents & Equipment Market Growth & Trends

The global transfection reagents & equipment market size is expected to reach USD 1.4 billion by 2025, expanding at a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The latest polymeric formulations-based compounds are gentle to cells as compared to cationic liposomes and these products render higher gene-delivery efficiency, further promoting the development of unique transfection products in the market.

Moreover, multi-component reagents such as X-tremeGENE provided by F. Hoffmann-La Roche AG, deliver high efficiency and minimal cytotoxicity than traditional ones comprising only one-component formulations. Thus, companies are keen on offering cutting-edge transfection solutions, in turn, offering significant momentum to market growth.

The gene expression studies segment dominated the market and account for the largest revenue share in 2019. This is attributed to the rising focus on the translation of genomic information in clinics. In addition, an increasing number of research projects related to the identification of chromosomal anomalies is anticipated to propel segment growth.

 Request a free sample copy or view report summary: Transfection Reagents & Equipment Market Report

Transfection Reagents & Equipment Market Report Highlights

• The reagents segment accounted for the highest revenue of USD 465.9 million in 2019 and is anticipated to maintain this trend throughout the forecast period

• This is attributed to the heavy investments by manufacturers including F. Hoffmann-La Roche AG in the development of multicomponent-based products

• Lipofection is emerging as a lucrative technique, which can be attributed to its wide acceptance across sequential, reverse, multiple, transient, and co-transfection

• Moreover, high protocol variability allows lipofection to be used for transfection of all types of nucleic acids and also contributes to the revenue generation by this segment

• Biomedical research includes the application of transfection reagents across mutational analysis, library screening, and preclinical testing. This segment is estimated to witness the fastest growth rate of more than 8.0% during the study period

• North America generated maximum revenue of 40.0% in 2019 attributed to the sufficient presence of skilled professionals along with the strong network of original equipment manufacturers

• Market participants are keen on expanding their product portfolios aimed at sustaining market competition

• For instance, in July 2019, Mirus Bio launched TransIT-VirusGEN SELECT Transfection Reagent, intended to be used in the drug discovery process in gene and cell manufacturing. The substance simplifies the qualifying process of ancillary materials employed in viral vectors manufacturing for preclinical and early-phase clinical trials.

Transfection Reagents & Equipment Market Segmentation

Grand View Research has segmented the global transfection reagents and equipment market on the basis of product, method, application, and region:

Transfection Reagents & Equipment Product Outlook (Revenue, USD Million, 2014 - 2025)

• Reagents

• Equipment

Transfection Reagents & Equipment Method Outlook (Revenue, USD Million, 2014 - 2025)

• Electroporation

• Liposomes

• Particle Bombardment

• Microinjection

• Adenoviral Vectors

• Calcium Phosphate

• DEAE-dextran

• Magnetic Beads

• Activated Dendrimers

• Laserfection

Transfection Reagents & Equipment Application Outlook (Revenue, USD Million, 2014 - 2025)

• Gene Expression Studies

• Protein Production

• Transgenic Models

• Therapeutic Delivery

• Cancer Research

• Biomedical Research

Transfection Reagents & Equipment Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America

  • The U.S.

  • Canada

• Europe

  • The U.K.

  • Germany

• Asia Pacific

  • Japan

  • China

• Latin America

  • Brazil

• MEA

  • South Africa

List of Key Players of Transfection Reagents & Equipment Market

• Thermo Fisher Scientific, Inc.

• Promega Corporation

• Lonza

• QIAGEN

• F. Hoffmann-La Roche Ltd.

• Bio-Rad Laboratories Inc.

• Merck KGaA

• OriGene Technologies Inc.

• MaxCyte, Inc.

• POLYPLUS TRANSFECTION

• Horizon Discovery Ltd.

• PromoCell GmbH.